Contact this trialFirst, we need to learn more about you.
Cytotoxic Chemotherapy Agent
Radium-223 + Docetaxel for Prostate Cancer
Recruiting2 awardsPhase 3
Omaha, Nebraska
This trial is comparing the efficacy of adding Radium-223 to Docetaxel chemotherapy versus Docetaxel chemotherapy alone in men with metastatic hormone-refractory prostate cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.